A Replacement for Warfarin

HomeCirculationVol. 116, No. 2A Replacement for Warfarin Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBA Replacement for WarfarinThe Search Continues John W. Eikelboom, MD and Jeffrey I. Weitz, MD John W. EikelboomJohn W. Eikelboom From the Departments of Medicine (J.W.E., J.I.W.) and Biochemistry and Biomedical Sciences (J.I.W.), McMaster University and Henderson Research Centre, Hamilton, Ontario, Canada. Search for more papers by this author and Jeffrey I. WeitzJeffrey I. Weitz From the Departments of Medicine (J.W.E., J.I.W.) and Biochemistry and Biomedical Sciences (J.I.W.), McMaster University and Henderson Research Centre, Hamilton, Ontario, Canada. Search for more papers by this author Originally published18 Jun 2007https://doi.org/10.1161/CIRCULATIONAHA.107.712349Circulation. 2007;116:131–133Other version(s) of this articleYou are viewing the most recent version of this article. Previous versions: June 18, 2007: Previous Version 1 Vitamin K antagonists (VKAs) such as warfarin are the only oral anticoagulants currently available for clinical use. Warfarin has numerous limitations, including slow onset and offset of action, a narrow therapeutic window, and a metabolism that is affected by diet, drugs, and genetic polymorphisms.1 Because of its unpredictable dose response, warfarin requires careful coagulation monitoring to ensure that a therapeutic anticoagulant effect is achieved.2 Variable dose requirements, concern about the risk of bleeding, and the need for frequent coagulation monitoring have prompted the development of new oral anticoagulants to replace warfarin. With a predictable anticoagulant response and little potential for food or drug interactions, these new agents have been designed to be administered in fixed doses without coagulation monitoring. Consequently, these drugs have the potential to simplify long-term anticoagulant therapy.Article p 180The features of the new oral anticoagulants in the most advanced stages of clinical development are listed in the Table and are compared with those of warfarin. Unlike warfarin, which reduces the functional levels of factors II (prothrombin), VII, IX, and X, these novel agents are directed against the active site of factor Xa or thrombin, the enzymes responsible for thrombin generation and fibrin formation, respectively (see the Figure). Rivaroxaban and apixaban target factor Xa, whereas dabigatran etexilate inhibits thrombin. Comparison of Warfarin to New Oral Anticoagulants in Advanced Stages of Clinical DevelopmentDrugTargetDosingCoagulation MonitoringHalf-Life, hRenal Clearance, %InteractionsIndicationsAF indicates atrial fibrillation.*Includes ketoconazole, macrolides (eg, clarithromycin), and protease inhibitors (eg, atanazavir).†Moderately reduces absorption.RivaroxabanFactor XaFixed, once dailyNo965Potent CYP3A4 inhibitors*VTE prevention and treatment, stroke prevention in AF, acute coronary syndromesApixabanFactor XaFixed, twice dailyNo9–1425Potent CYP3A4 inhibitors*VTE prevention and treatment, stroke prevention in AF, acute coronary syndromesDabigatran etexilateFactor IIa (thrombin)Fixed, twice dailyNo14–17100Proton pump inhibitors†VTE prevention and treatment, stroke prevention in AF, acute coronary syndromesWarfarinVitamin K epoxide reductaseVariable, once dailyYes400Multiple drugs, dietary vitamin KVTE prevention and treatment, stroke prevention in AF, secondary prevention after myocardial infarction, mechanical heart valvesDownload figureDownload PowerPointTargets of new oral anticoagulant drugs. Oral factor Xa inhibitors (rivaroxaban, apixaban) bind directly to factor Xa and prevent thrombin generation. Dabigatran etexilate, an orally active direct thrombin inhibitor, undergoes metabolic activation to dabigatran, which binds to the active site of thrombin (factor IIa) and blocks its capacity to convert fibrinogen to fibrin, to activate platelets, and to amplify its own generation by activating factors V, VIII, and XI. By blocking the active site of thrombin, dabigatran also blocks the activation of protein C and thrombin-activatable fibrinolysis inhibitor by the thrombin/thrombomodulin complex. TF indicates tissue factor.Rivaroxaban is a small molecule directed against the active site of factor Xa. After oral administration, it is absorbed in the stomach and small intestine with a bioavailability of 60% to 80%. Peak plasma levels are achieved in 3 hours, and the drug circulates with a half-life of 9 hours. Rivaroxaban is cleared via 2 pathways: ≈65% is excreted unchanged in the urine, and the remainder is eliminated through the biliary/fecal route. Because of the predominance of the renal pathway of excretion, the half-life of rivaroxaban is prolonged in the elderly and in patients with renal impairment.3 Apixaban has properties similar to those of rivaroxaban except that the clearance of apixaban is mainly via the biliary/fecal route. Therefore, apixaban is less likely to accumulate in patients with renal insufficiency than is rivaroxaban.4As direct inhibitors of factor Xa, rivaroxaban and apixaban inactivate free factor Xa and factor Xa incorporated within the prothrombinase complex equally well. In contrast, indirect factor Xa inhibitors such as fondaparinux have reduced capacity to inhibit factor Xa when it is incorporated within the prothrombinase complex. Whether inhibition of platelet-bound factor Xa endows direct factor Xa inhibitors with an advantage over indirect inhibitors remains to be established.The clinical development of rivaroxaban is more advanced than that of apixaban.3 Favorable early results with rivaroxaban for the prevention of venous thromboembolism (VTE) in patients undergoing major orthopedic surgery5–7 prompted its recent evaluation in phase II clinical trials for the treatment of patients with acute symptomatic VTE. In the present issue of Circulation, Agnelli and colleagues8 report the results of the Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis (ODIXa-DVT) study, a phase II randomized trial of rivaroxaban for the treatment of DVT. In that trial, 613 patients with symptomatic proximal DVT who did not have pulmonary embolism were randomized to receive fixed-dose oral rivaroxaban (at doses of 10, 20, or 30 mg twice daily or 40 mg once daily) or subcutaneous enoxaparin (at a dose of 1 mg/kg twice daily), followed by a VKA. Allocation to rivaroxaban or enoxaparin/VKA treatment was open label, but patients and investigators were blinded to the dose of rivaroxaban, and all outcomes were adjudicated centrally without knowledge of treatment allocation. The primary efficacy outcome was improvement in thrombotic burden (assessed by repeating the compression ultrasound and comparing the test results with those done at baseline) without recurrent symptomatic VTE or VTE-related death. The primary efficacy outcome occurred in 44% to 59% of patients receiving rivaroxaban and in 46% of those randomized to enoxaparin/VKA. There was no indication of a dose–efficacy relationship with rivaroxaban, but the incidence of bleeding (major plus minor) was higher with increasing doses of rivaroxaban, ranging from 5.0% to 11.6%, compared with a rate of 6.3% in patients treated with enoxaparin/VKA. Symptomatic VTE or death occurred in 2.1% of patients treated with rivaroxaban and in 0.9% of those given enoxaparin/VKA.The ODIXa-DVT study is one of a pair of phase II trials evaluating the efficacy and safety of rivaroxaban for the treatment of DVT. Its companion study, the as-yet unpublished EINSTEIN-DVT trial,9 was of similar design but compared once-daily rivaroxaban (in doses of 20, 30, or 40 mg) with a heparin (either unfractionated heparin or low-molecular-weight heparin), followed by a VKA, in 543 patients with symptomatic DVT without associated symptomatic pulmonary embolism. The primary efficacy outcome was deterioration in thrombotic burden (assessed by repeating the compression ultrasound and perfusion lung scan at 12 weeks and comparing the results with those obtained at baseline) or symptomatic recurrent VTE. This outcome occurred in 5.4% to 6.6% of patients randomized to rivaroxaban and in 9.9% of those given heparin/VKA. Again, there was no evidence of a dose–efficacy relationship with rivaroxaban, but in contrast to the results of the ODIXa-DVT trial, there was no dose response for bleeding. Clinically relevant bleeding occurred in 2.9% to 7.5% of patients randomized to rivaroxaban and in 8.8% of those treated with heparin/VKA.The lack of a dose–efficacy response for rivaroxaban in the ODIXa-DVT trial, which evaluated total daily rivaroxaban doses ranging from 20 to 60 mg, and in the EINSTEIN-DVT trial,9 which examined daily doses ranging from 20 to 40 mg, suggests that there is a plateau for efficacy in this dose range. The significant dose relationship for bleeding with twice-daily administration, but not with once-daily dosing, raises the possibility that dose frequency might influence bleeding risk independently of dose intensity. This could occur if the sustained drug levels achieved with twice-daily dosing confer a greater bleeding risk than the high peak levels obtained with once-daily drug administration. However, comparison across these trials is potentially confounded by differences in the comparators, cointerventions, and outcome definitions. In the ODIXa-DVT trial, the major bleeding rates with 40 mg rivaroxaban once daily or 20 mg twice daily were both 1.7%, whereas the minor bleeding rates were 9.9% and 7.7% with once-daily and twice-daily dosing, respectively. These findings suggest that if dose frequency does influence the bleeding risk, its effect is likely to be minor.The results of the ODIXa-DVT and EINSTEIN-DVT trials provide proof of principle for the efficacy and safety of rivaroxaban for the treatment of DVT. On the basis of these trials, the 20-mg once-daily dose of rivaroxaban has been chosen for evaluation in phase III randomized trials of rivaroxaban for the treatment of VTE and for the prevention of stroke in atrial fibrillation.3 However, has the optimal dose been identified in these phase II trials? The lack of a dose–efficacy response with daily rivaroxaban doses ranging from 20 to 60 mg suggests that lower doses also may be effective. For example, it is possible that the 10-mg once-daily dose that is currently being evaluated in phase III studies for the prevention of VTE in major orthopedic surgery3 would maintain efficacy for treatment of VTE while reducing the risk of bleeding. Support for the concept that lower anticoagulant doses may reduce bleeding without compromising antithrombotic efficacy is provided by the results of the Organization to Assess Strategies for Ischemic Syndromes 5 (OASIS-5) trial.10 In this study, the dose of fondaparinux used for VTE prophylaxis11 was as effective as conventional treatment doses of enoxaparin at preventing recurrent ischemia in patients with non–ST-elevation acute coronary syndromes. However, this low-dose fondaparinux regimen was associated with a 50% reduction in the risk of major and minor bleeding. These observations raise the possibility that more work should be done to determine the optimal dose of rivaroxaban to carry forward into the phase III program.The composite primary efficacy outcomes in the ODIXa-DVT and EINSTEIN-DVT trials were driven primarily by changes in thrombotic burden as assessed by repeated compression ultrasonography and perfusion lung scanning. Previous studies have shown that venographic assessment of thrombus burden using the Marder score is a valid surrogate for recurrent DVT.12 Compression ultrasonography has largely replaced venography because compression ultrasonography is noninvasive and obviates the need for injection of contrast dye. In the ODIXa-DVT trial, changes in compression ultrasound findings were quantified with an adapted Marder score. Although this is a logical approach, such an ultrasound scoring system has never been directly compared with its venographic counterpart. Nonetheless, assessment of thrombus burden with repeated compression ultrasound examinations has been used successfully in phase II dose-finding studies with other anticoagulants.13,14Unexpected hepatotoxicity during recent randomized evaluation of ximelagatran, the first oral direct thrombin inhibitor, has prompted intense scrutiny of the potential hepatic side effects of new oral anticoagulants, including rivaroxaban. During the first 3 weeks of treatment in the ODIXa-DVT trial, the incidence of alanine aminotransferase elevations >3 times the upper limit of normal was significantly lower in patients treated with rivaroxaban than it was in those given enoxaparin/VKA. This is not surprising because enoxaparin is known to transiently increase the levels of transaminases. After 3 weeks, the incidences of alanine aminotransferase elevations were low with both treatments. No patients in the enoxaparin/VKA group stopped treatment because of elevated liver enzymes, whereas 3 patients stopped treatment early in the rivaroxaban group, 2 of whom died soon thereafter of unrelated hepatic causes (metastatic malignancy and acute hepatitis B, respectively). There has been no suggestion of adverse hepatic effects with rivaroxaban in phase II trials for VTE prevention,5–7 but more long-term data are needed.While the studies with rivaroxaban are well underway, apixaban and dabigatran etexilate are being evaluated in parallel development programs. Building on data from phase II trials for the prevention and treatment of VTE, apixaban has entered phase III evaluation for the prevention of VTE after major orthopedic surgery, for VTE prevention in medical patients, and for stroke prevention in atrial fibrillation. In contrast to rivaroxaban, a twice-daily regimen is being evaluated for these indications.Of the new oral anticoagulants, dabigatran etexilate is the drug in the most advanced stages of development. An oral direct thrombin inhibitor, dabigatran etexilate is a double prodrug that undergoes esterase-mediated conversion to dabigatran, a small molecule that targets the active site of thrombin. A phase III trial comparing 2 different doses of once-daily oral dabigatran etexilate with subcutaneous dalteparin for VTE prophylaxis after knee replacement surgery revealed similar efficacy and safety.15 Other phase III orthopedic trials have been completed, and phase III studies evaluating dabigatran etexilate for VTE treatment and for stroke prevention in atrial fibrillation are ongoing.Which is the better target, factor Xa or thrombin? Head-to-head trials of oral direct factor Xa and thrombin inhibitors are needed to address this question. Nonetheless, with the results of these clinical trials beginning to unfold, we are coming closer to finding a safer and more convenient replacement for warfarin.The opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.DisclosuresDr Weitz is a consultant for Bayer and served as a member of the independent central adjudication committee for ODIXa-DVT. Dr Eikelboom has received consulting fees and/or research funding from companies that are developing new anticoagulants (Bristol-Myers Squibb, Boehringer Ingelheim, Johnson & Johnson, Pfizer, and Sanofi-Aventis).FootnotesCorrespondence to Dr Jeffrey Weitz, Henderson Research Centre, 711 Concession St, Hamilton, Ontario, L8V 1C3, Canada. E-mail [email protected] References 1 Hirsh J. Oral anticoagulant drugs. N Engl J Med. 1991; 324: 1865–1875.CrossrefMedlineGoogle Scholar2 Bates SM, Weitz JI. The status of new anticoagulants. Br J Haematol. 2006; 134: 3–19.CrossrefMedlineGoogle Scholar3 Weitz JI. Emerging anticoagulants for the treatment of venous thromboembolism. Thromb Haemost. 2006; 96: 274–284.CrossrefMedlineGoogle Scholar4 Turpie AG. Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. Arterioscler Thromb Vasc Biol. 2007; 27: 1238–1247.LinkGoogle Scholar5 Turpie AG, Fisher WD, Bauer KA, Kwong LM, Irwin MW, Kalebo P, Misselwitz F, Gent M, for the ODIXa-Knee Study Group. BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement: a phase II dose-ranging study. J Thromb Haemost. 2005; 3: 2479–2486.CrossrefMedlineGoogle Scholar6 Eriksson BI, Borris L, Dahl OE, Haas S, Huisman MV, Kakkar AK, Misselwitz F, Kalebo P, for the ODIXa-HIP Study Investigators. Oral, direct factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost. 2006; 4: 121–128.CrossrefMedlineGoogle Scholar7 Eriksson BI, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, Muehlhofer E, Dierig C, Misselwitz F, Kalebo P, for the ODIXa-HIP Study Investigators. A once-daily, oral, direct factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation. 2006; 114: 2374–2381.LinkGoogle Scholar8 Agnelli G, Gallus A, Goldhaber SZ, Haas S, Huisman MV, Hull RD, Kakkar AK, Misselwitz F, Schellong S, for the ODIXa-DVT Study Investigators. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study. Circulation. 2007; 116: 180–187.LinkGoogle Scholar9 Buller HR, for the EISTEIN-DVT Study Group. Once daily treatment with an oral, direct factor Xa inhibitor—rivaroxaban (BAY 59-7939)—in patients with acute, symptomatic deep vein thrombosis: the EINSTEIN-DVT dose-ranging study. Eur Heart J. 2006; 27: 761. Abstract.CrossrefMedlineGoogle Scholar10 Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, Budaj A, Peters RJ, Bassand JP, Wallentin L, Joyner C, Fox KA, for the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med. 2006; 354: 1464–1476.CrossrefMedlineGoogle Scholar11 Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med. 2002; 162: 1833–1840.CrossrefMedlineGoogle Scholar12 Hull RD, Marder VJ, Mah AF, Biel RK, Brant RF. Quantitative assessment of thrombus burden predicts the outcome of treatment for venous thrombosis: a systematic review. Am J Med. 2005; 118: 456–464.CrossrefMedlineGoogle Scholar13 Rembrandt Investigators. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti-factor Xa activity: a phase II evaluation. Circulation. 2000; 102: 2726–2731.CrossrefMedlineGoogle Scholar14 PERSIST Investigators. A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis: a phase II evaluation. J Thromb Haemost. 2004; 2: 47–53.CrossrefMedlineGoogle Scholar15 Eriksson BI, Dahl OE, van Dijk CN, Frostick SP, Kurth AA, Rosencher N, Schnee J, Hettiarachchi R, Christiansen AY, Hantel S, Büller HR. A new oral anticoagulant, dabigatran etexilate, is effective and safe in preventing venous thromboembolism after total knee replacement surgery (the RE-MODEL Trial). Blood. 2006; 108: 573. Abstract.CrossrefGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Bauersachs R (2016) Non-vitamin K antagonist oral anticoagulants for the prevention of recurrent venous thromboembolism, Thrombosis Research, 10.1016/j.thromres.2016.05.022, 144, (12-20), Online publication date: 1-Aug-2016. Ogata K, Shimizu T, Masumoto H, Oguma T, Sugiyama N and Kunitada S (2015) Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Novel Factor Xa Inhibitor DY-807f in Healthy Volunteers, Thrombosis Research, 10.1016/j.thromres.2014.12.028, 135:4, (594-601), Online publication date: 1-Apr-2015. Bollati M, Moretti C, Sciuto F, Omedè P, Marra W, Morello M, Grimaldi R, Rabbia C, Zoccai G and Sheiban I (2015) Postpartum valve thrombosis, Journal of Cardiovascular Medicine, 10.2459/JCM.0b013e328341033d, 16, (S49-S50), Online publication date: 1-Jan-2015. Eriksson B, Agnelli G, Gallus A, Lassen M, Prins M, Renfurm R, Kashiwa M and Turpie A (2017) Darexaban (YM150) versus enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a randomised phase IIb dose confirmation study (ONYX-3), Thrombosis and Haemostasis, 10.1160/TH13-04-0296, 111:02, (213-225), . Groenendaal D, Strabach G, Garcia-Hernandez A, Kadokura T, Heeringa M, Mol R, Eltink C and Onkels H (2013) The pharmacokinetics of darexaban are not affected to a clinically relevant degree by rifampicin, a strong inducer of P-glycoprotein and CYP3A4, British Journal of Clinical Pharmacology, 10.1111/j.1365-2125.2012.04346.x, 75:2, (440-449), Online publication date: 1-Feb-2013. Obonska K, Navarese E, Lansky A, Tarantini G, Rossini R, Kozinski M, Musumeci G, Di Pasquale G, Górny B, Szczesniak A, Kowalewski M, Gurbel P and Kubica J (2013) Low-dose of oral factor Xa inhibitors in patients with a recent acute coronary syndrome: A systematic review and meta-analysis of randomized trials, Atherosclerosis, 10.1016/j.atherosclerosis.2013.04.022, 229:2, (482-488), Online publication date: 1-Aug-2013. Wilkinson P (2012) New oral anticoagulants: an alternative to warfarin, British Journal of Hospital Medicine, 10.12968/hmed.2012.73.9.498, 73:9, (498-501), Online publication date: 1-Sep-2012. Deitelzweig S, Lin J and Lin G (2011) Preventing Venous Thromboembolism Following Orthopedic Surgery in the United States, Clinical and Applied Thrombosis/Hemostasis, 10.1177/1076029611404215, 17:6, (640-650), Online publication date: 1-Nov-2011. Steg P, Mehta S, Jukema J, Lip G, Gibson C, Kovar F, Kala P, Garcia-Hernandez A, Renfurm R and Granger C (2011) RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome, European Heart Journal, 10.1093/eurheartj/ehr334, 32:20, (2541-2554), Online publication date: 1-Oct-2011., Online publication date: 1-Oct-2011. Huo M (2017) New oral anticoagulants in venous thromboembolism prophylaxis in orthopaedic patients: Are they really better?, Thrombosis and Haemostasis, 10.1160/TH10-10-0653, 106:07, (45-57), . Eikelboom J, O'Donnell M, Yusuf S, Diaz R, Flaker G, Hart R, Hohnloser S, Joyner C, Lawrence J, Pais P, Pogue J, Synhorst D and Connolly S (2010) Rationale and design of AVERROES: Apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment, American Heart Journal, 10.1016/j.ahj.2009.08.026, 159:3, (348-353.e1), Online publication date: 1-Mar-2010. Ogata K, Mendell-Harary J, Tachibana M, Masumoto H, Oguma T, Kojima M and Kunitada S (2013) Clinical Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Factor Xa Inhibitor Edoxaban in Healthy Volunteers, The Journal of Clinical Pharmacology, 10.1177/0091270009351883, 50:7, (743-753), Online publication date: 1-Jul-2010. Halley C and Klein A (2010) Antithrombotic Therapy for Atrial Fibrillation and Cardioversion Antithrombotic Drug Therapy in Cardiovascular Disease, 10.1007/978-1-60327-235-3_20, (389-403), . Torella M, Torella D, Chiodini P, Franciulli M, Romano G, De Santo L, De Feo M, Amarelli C, Sasso F, Salvatore T, Ellison G, Indolfi C, Cotrufo M and Nappi G (2010) LOWERing the INtensity of oral anticoaGulant Therapy in patients with bileaflet mechanical aortic valve replacement: Results from the “LOWERING-IT” Trial, American Heart Journal, 10.1016/j.ahj.2010.05.005, 160:1, (171-178), Online publication date: 1-Jul-2010. Maegdefessel L, Linde T, Krapiec F, Hamilton K, Steinseifer U, van Ryn J, Raaz U, Buerke M, Werdan K and Schlitt A (2010) In vitro comparison of dabigatran, unfractionated heparin, and low-molecular-weight heparin in preventing thrombus formation on mechanical heart valves, Thrombosis Research, 10.1016/j.thromres.2010.06.011, 126:3, (e196-e200), Online publication date: 1-Sep-2010. Levy J and Azran M (2010) Anesthetic concerns for patients with coagulopathy, Current Opinion in Anaesthesiology, 10.1097/ACO.0b013e328339480a, 23:3, (400-405), Online publication date: 1-Jun-2010. Turpie A (2009) Thromboprophylaxis After Major Orthopaedic Surgery: State of the Art European Instructional Lectures, 10.1007/978-3-642-00966-2_4, (29-38), . Hlinomaz O (2009) Antithrombotic therapy after acute myocardial infarction, Cor et Vasa, 10.33678/cor.2009.028, 51:2, (112-117), Online publication date: 1-Feb-2009. Hughes S and Messerly S (2009) Progress in Prevention, Journal of Cardiovascular Nursing, 10.1097/JCN.0b013e318197b5c5, 24:2, (171-173), Online publication date: 1-Mar-2009. Stewart R (2009) Clinical trials in heart valve disease, Current Opinion in Cardiology, 10.1097/HCO.0b013e32832b40e1, 24:4, (279-287), Online publication date: 1-Jul-2009. Eikelboom J and Weitz J (2008) Selective factor Xa inhibition for thromboprophylaxis, The Lancet, 10.1016/S0140-6736(08)60879-X, 372:9632, (6-8), Online publication date: 1-Jul-2008. Janjigian M and Muhs B (2008) Current Treatment of Acute Lower Extremity Deep Venous Thrombosis, The International Journal of Lower Extremity Wounds, 10.1177/1534734608314566, 7:1, (15-20), Online publication date: 1-Mar-2008. Harenberg J (2008) Indirect and direct anticoagulants predominantly inhibiting factor Xa, Therapy, 10.2217/14750708.5.2.177, 5:2, (177-192), Online publication date: 1-Mar-2008. July 10, 2007Vol 116, Issue 2 Advertisement Article InformationMetrics https://doi.org/10.1161/CIRCULATIONAHA.107.712349PMID: 17576860 Originally publishedJune 18, 2007 KeywordsanticoagulantsEditorialsthrombosisPDF download Advertisement SubjectsAnticoagulantsPlatelets